VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 45,700 Shares of Elanco Animal Health Incorporated $ELAN

VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 21.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 257,573 shares of the company’s stock after acquiring an additional 45,700 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.05% of Elanco Animal Health worth $5,767,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ELAN. BlackRock Inc. bought a new position in shares of Elanco Animal Health in the second quarter worth about $1,202,198,000. Primecap Management Co. CA bought a new stake in Elanco Animal Health during the 2nd quarter valued at approximately $1,118,402,000. The Manufacturers Life Insurance Company purchased a new position in Elanco Animal Health in the 2nd quarter worth approximately $205,636,000. Sei Investments Co. lifted its holdings in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after purchasing an additional 4,975,721 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Elanco Animal Health in the 2nd quarter worth approximately $83,958,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. UBS Group increased their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They set a “buy” rating and a $32.00 target price for the company. Finally, Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Insiders Place Their Bets

In other news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company’s stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence Kurzius purchased 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. This trade represents a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 63,198 shares of company stock worth $1,473,109. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Down 0.1%

Shares of ELAN opened at $23.04 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a market capitalization of $11.51 billion, a price-to-earnings ratio of -56.20, a price-to-earnings-growth ratio of 2.05 and a beta of 1.73. Elanco Animal Health Incorporated has a 1 year low of $19.40 and a 1 year high of $27.98. The business’s 50 day simple moving average is $23.13 and its 200-day simple moving average is $23.82.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.